Antiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping their anti-androgen. But does this happen with today's 2nd generation antiandrogens?
--------
9:53
June 2025 Updates
A plethora of recent updates:
-Pembrolizumab (perioperative) in head & neck cancer (Keynote-689)
-Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib
-Pirtobrutinib improves PFS in CLL
-Zanubrutinib has a new dosage form on the way
-Another mitomycin product approved with "reverse thermal properties"
-A new regimen for FL of tafasitamab/rituximab/lenalidomide
-A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options
--------
27:37
ASCO 2025
A recap of notable updates from ASCO 2025
1. Destiny-Breast09
2. BREAKWATER
3. ATOMIC
4. Delphi-304
5. CM 816 OS update
6. C-POST
7. Matterhorn
--------
14:15
CLEOPATRA
Our Landmarks of OncoPharm series returns to discuss the CLEOPATRA study, which established docetaxel, trastuzumab, pertuzumab (THP) as a standard first-line regimen for metastatic HER2-amplified breast cancer.
--------
11:17
Talking about cancer misinformation
If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you.
1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.21857
2. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Brasil